Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.creator | Shan, Z. (Zhao) | - |
dc.creator | Álvarez-Sola, G. (Gloria) | - |
dc.creator | Uriarte, I. (Iker) | - |
dc.creator | Arechederra, M. (María) | - |
dc.creator | García-Fernández-de-Barrena, M. (Maite) | - |
dc.creator | Berasain, C. (Carmen) | - |
dc.creator | Ju, C. (Cynthia) | - |
dc.creator | Avila, M.A. (Matías Antonio) | - |
dc.date.accessioned | 2022-10-19T08:05:47Z | - |
dc.date.available | 2022-10-19T08:05:47Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Shan, Z. (Zhao); Álvarez-Sola, G. (Gloria); Uriarte, I. (Iker); et al. "Fibroblast growth factors 19 and 21 in acute liver damage". Annals of translational medicine. 6 (12), 2018, 257 | es_ES |
dc.identifier.issn | 2305-5839 | - |
dc.identifier.uri | https://hdl.handle.net/10171/64494 | - |
dc.description.abstract | Currently there are very few pharmacological options available to treat acute liver injury. Because its natural exposure to noxious stimuli the liver has developed a strong endogenous hepatoprotective capacity. Indeed, experimental evidence exposed a variety of endogenous hepatic and systemic responses naturally activated to protect the hepatic parenchyma and to foster liver regeneration, therefore preserving individual’s survival. The fibroblast growth factor (FGF) family encompasses a range of polypeptides with important effects on cellular differentiation, growth survival and metabolic regulation in adult organisms. Among these FGFs, FGF19 and FGF21 are endocrine hormones that profoundly influence systemic metabolism but also exert important hepatoprotective activities. In this review, we revisit the biology of these factors and highlight their potential application for the clinical management of acute liver injury | es_ES |
dc.description.sponsorship | This work was supported by Ministerio de Economía (Mineco), Spain (grant numbers SAF 2016- 75972R, SAF2014-54191R and SAF 2017-88933R), Ministerio de Sanidad, Instituto Carlos III, Spain (grant number FIS PI16/01126) and the National Institutes of Health USA (U01AA021723, R21AA024636, R01DK109574). Marie Curie EU contract to MGF-B. Fundación La Caixa Hepacare Project; Fundación Eugenio Rodríguez Pascual; Fundación M. Torres; Fundación Fuentes Dutor; Fundación Mario Losantos; Fundación Familia Puig-Infante; BiO-Eusko Fundazioa, Spain (grant number BIO15/CA/011). The generous support of Mr. Eduardo Avila and Mr. Sergio Durá is highly appreciated | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | AME Publishing | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Acute liver injury | es_ES |
dc.subject | Fibroblast growth factor 19 (FGF19) | es_ES |
dc.subject | Fibroblast growth factor 21 (FGF21) | es_ES |
dc.title | Fibroblast growth factors 19 and 21 in acute liver damage | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | 10.21037/ atm.2018.05.26 | - |
dadun.citation.number | 12 | es_ES |
dadun.citation.publicationName | Annals of translational medicine | es_ES |
dadun.citation.startingPage | 257 | es_ES |
dadun.citation.volume | 6 | es_ES |
Ficheros en este ítem:
Estadísticas e impacto
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.